Use of vegf-d in the diagnosis of lymphangioleiomyomatosis (lam) disease
AssigneesUniversity of Cincinnati, Children's Hospital Medical Center
InventorsFrancis X. McCormack, Lisa R. Young
Life of this patent
Estimating the term…
Abstract
Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided.
Claims33
A method of diagnosis of lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder comprising:
- (a) determining VEGF-D concentration in a biological sample from a human subject that has tuberoussclerosis complex (TSC) or a cystic or chylous lung disorder, and
- (b) diagnosing the presence or absence of LAM from the VEGF-D concentration, wherein LAM correlates with elevated VEGF-D concentration in the sample, compared to VEGF-D concentration in subjects with TSC or another cystic or chylous lung disorder that are free of LAM.
A method of diagnosis comprising:
- (a) diagnosing the presence of TSC or a cystic or chylous lung disorder in a human subject;
- (b) determining VEGF-D concentration in a biological sample from said subject;
- and
- (c) diagnosing the presence or absence of LAM from the VEGF-D concentration, wherein LAM correlates with elevated VEGF-D concentration in the sample compared to VEGF-D in subjects with TSC or another cystic or chylous lung disorder that are free of LAM.
A method of differentiating LAM from TSC or a cystic or chylous lung disorder respiratory disorder comprising
- (a) obtaining a measurement of VEGF-D from a human subject;
- and
- (b) differentiating LAM from TSC or a cystic or chylous lung disorder by comparing the level of VEGF-D in the sample to a predetermined criterion.
A method of predicting whether a human subject with TSC, or a cystic or chylous lung disorder has LAM comprising
- (a) determining VEGF-D concentration in a biological sample from said human subject, and
- (b) predicting whether the subject has LAM from the VEGF-D concentration,
Use of a VEGF-D antibody for screening a subject with TSC or a cystic or chyloud lung disorder to determine whether the subject has LAM.
Dependencies are inferred from the claim text.